Advertisement

Topics

Companies Related to "Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria" [Most Relevant Company Matches] RSS

04:30 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria" found in our extensive corporate database of over 50,000 company records.

Showing "Study High Dose Cyclophosphamide Patients With Severe Aplastic" Companies 1–25 of 8,200+

Relevant

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.


Amarillo Biosciences Incorporated

Amarillo Biosciences, Inc., (ABI), is a biopharmaceutical company developing low-dose oral and topical interferon alpha. We are directing our research at the treatment of Behcet's Disease, and oral warts in HIV+ patients and chronic cough in idiopathic pulmonary fibrosis. Low-dose oral interferon is Fundamentally Different from high dose injectable interferon. In this site, we will show the fun...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...


Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

GammaWest Brachytherapy

Brachytherapy is an advanced cancer treatment. The word "brachy" is Greek for "close by" and refers to placing radioactive seeds or sources directly in the tumor. This procedure gives physicians and patients the important advantage of applying a higher dose of radiation directly to the tumor while sparing healthy tissue and surrounding organs. Brachytherapy is a localized, precise, radiation treat...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Broncho-Dose

Broncho-Dose Pharmacy provides home-delivered nebulizer medications. Our team of pharmacy specialists provides an outstanding level of customer service to respiratory patients nationwide.

TxCell

TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. It is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of autolo...

SharedClarity

SharedClarity is a unique joint effort between health care systems and UnitedHealthcare to use data from tens of millions of patients to study the long-term effectiveness of high-technology medical devices that have a high impact on patients. SharedClarity will use the results of the studies to select the best devices for patients and negotiate affordable ...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing ARS-1, an intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient and more reliable for patients and loved ones at...

CET CANCER CENTER

California Endocurietherapy Cancer Center (CET) is the first brachytherapy only center in the United States.Founded by D Jeffrey Demanes M.D. in 1981.Dedicated solely to High Dose Rate brachytherapy (HDR) since 1991.Most experienced HDR brachytherapy center.A training destination for physicians and residents.HDR treatment protocol developmentInnovation in high dose rate brachytherapy and equipment...

Ameritox

The single-group, multi-dose study examined the ability of the Rx Guardian(SM) algorithm to differentiate among low, medium and high daily doses of OxyContin®. Oxycodone levels were detected in the urine of 36 healthy volunteers using a liquid chromatography-mass spectrometry (LC-MS-MS) assay. Participants were randomized to receive 80mg, 160mg or 240mg of daily OxyContin® to steady state cond...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's imm...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. Our lead product, CORLUX, is currently in three Phase 3 clinical trials for the treatment of the psychotic features of psychotic major depression (PMD), a disorder that affects approximately three million adults in the United States ea...

Azaya Therapeutics Inc.

Azaya Therapeutics, Inc. is an oncology company focused on developing more effective cancer treatments through its novel nanotechnology platform. Azaya’s patented Protein Stabilized Liposomes™ (PSL) platform allows for high-dose delivery of potent cytotoxics with potentially lower side effects. ATI-1123, is a novel liposomal encapsulation of Doce...

Advanced Pain Remedies

Headquartered near Research Triangle Park, NC, APR is majority owned and virtually run by Cato BioVentures. APR will work with Advanced Targeting Systems, Cato Research and Cato BioVentures to develop and seek a partner to commercialize SP-SAP as a novel, non-opioid treatment for severe chronic pain. This technology is a single dose, microsurgery which is anticipated to have minimal adverse side e...


More From BioPortfolio on "Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks